Evotec buys Aptuit for nearly $300m

19:00 EDT 16 Aug 2017 | Pharmaceutical Technology

German company Evotec has completed the acquisition of Aptuit for a total consideration of approximately $300m to support its long-term strategy to be the industry partner of choice for external drug discovery and development innovation.

Original Article: Evotec buys Aptuit for nearly $300m


More From BioPortfolio on "Evotec buys Aptuit for nearly $300m"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...